116 related articles for article (PubMed ID: 8695351)
1. Induction of apoptosis in human cancer cell lines by the novel anthracenyl-amino acid topoisomerase I inhibitor NU/ICRF 505.
Meikle I; Cummings J; Macpherson JS; Smyth JF
Br J Cancer; 1996 Aug; 74(3):374-9. PubMed ID: 8695351
[TBL] [Abstract][Full Text] [Related]
2. Development of anthracenyl-amino acid conjugates as topoisomerase I and II inhibitors that circumvent drug resistance.
Cummings J; Macpherson JS; Meikle I; Smyth JF
Biochem Pharmacol; 1996 Oct; 52(7):979-90. PubMed ID: 8831716
[TBL] [Abstract][Full Text] [Related]
3. Cytogenetic evaluation of the mechanism of cell death induced by the novel anthracenyl-amino acid topoisomerase II catalytic inhibitor NU/ICRF 500.
Cummings J; Sumner AT; Slavotinek A; Meikle I; Macpherson JS; Smyth JF
Mutat Res; 1995 Aug; 344(1-2):55-62. PubMed ID: 7565893
[TBL] [Abstract][Full Text] [Related]
4. Biochemistry of topoisomerase I and II inhibition by anthracenyl-amino acid conjugates.
Meikle I; Cummings J; Macpherson JS; Hadfield JA; Smyth JF
Biochem Pharmacol; 1995 Jun; 49(12):1747-57. PubMed ID: 7598737
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the major metabolite of the novel topoisomerase I inhibitor NU/ICRF 505.
Cummings J; Meikle I; Macpherson JS; Smyth JF
Anticancer Drug Des; 1996 Jul; 11(5):367-82. PubMed ID: 8765530
[TBL] [Abstract][Full Text] [Related]
6. Cell cycle effects of the novel topoisomerase I inhibitor NU/ICRF 505 in a panel of Chinese hamster ovary cell lines.
Macpherson JS; Cummings J; Meikle I; Miller EP; Smyth JF
Eur J Cancer; 1997 Feb; 33(2):280-3. PubMed ID: 9135500
[TBL] [Abstract][Full Text] [Related]
7. Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation.
Cummings J; Boyd G; Ethell BT; Macpherson JS; Burchell B; Smyth JF; Jodrell DI
Biochem Pharmacol; 2002 Feb; 63(4):607-13. PubMed ID: 11992628
[TBL] [Abstract][Full Text] [Related]
8. Identification of anthracenyl-dipeptide conjugates as novel topoisomerase I and II inhibitors and their evaluation as potential anticancer drugs.
Meikle I; Cummings J; Macpherson JS; Smyth JF
Anticancer Drug Des; 1995 Oct; 10(7):515-27. PubMed ID: 7495476
[TBL] [Abstract][Full Text] [Related]
9. Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins.
Cummings J; Zelcer N; Allen JD; Yao D; Boyd G; Maliepaard M; Friedberg TH; Smyth JF; Jodrell DI
Biochem Pharmacol; 2004 Jan; 67(1):31-9. PubMed ID: 14667926
[TBL] [Abstract][Full Text] [Related]
10. Molecular modeling of the interaction of anthracenyl-amino acid topoisomerase inhibitors with the DNA sequence d(CGTACG).
Cummings J; Hadfield JA; Meikle I; McGown AT; Smyth JF
Anticancer Drugs; 1996 Aug; 7(6):636-41. PubMed ID: 8913431
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibition of topoisomerase II by ICRF-193 does not support a role for topoisomerase II activity in the fragmentation of chromatin during apoptosis of human leukemia cells.
Beere HM; Chresta CM; Hickman JA
Mol Pharmacol; 1996 May; 49(5):842-51. PubMed ID: 8622634
[TBL] [Abstract][Full Text] [Related]
12. Accumulation of anthracenyl-amino acid topoisomerase I and II inhibitors in drug-sensitive and drug-resistant human ovarian cancer cell lines determined by high-performance liquid chromatography.
Cummings J; Meikle I; Macpherson JS; Smyth JF
Cancer Chemother Pharmacol; 1995; 37(1-2):103-9. PubMed ID: 7497578
[TBL] [Abstract][Full Text] [Related]
13. Determination of the novel topoisomerase I inhibitor NU/ICRF 505 and its major metabolite in plasma, tissue and tumour by high-performance liquid chromatography.
Cummings J; Meikle I; Macpherson JS; Smyth JF
J Chromatogr B Biomed Appl; 1996 Oct; 685(1):159-64. PubMed ID: 8930764
[TBL] [Abstract][Full Text] [Related]
14. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors.
Dubrez L; Goldwasser F; Genne P; Pommier Y; Solary E
Leukemia; 1995 Jun; 9(6):1013-24. PubMed ID: 7596166
[TBL] [Abstract][Full Text] [Related]
15. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Morgan SE; Cadena RS; Raimondi SC; Beck WT
Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
[TBL] [Abstract][Full Text] [Related]
16. DNA damage and cell killing by camptothecin and its derivative in human leukemia HL-60 cells.
Yoshida A; Ueda T; Wano Y; Nakamura T
Jpn J Cancer Res; 1993 May; 84(5):566-73. PubMed ID: 8391526
[TBL] [Abstract][Full Text] [Related]
17. Apoptosis and its modulation in human promyelocytic HL-60 cells treated with DNA topoisomerase I and II inhibitors.
Bertrand R; Solary E; Jenkins J; Pommier Y
Exp Cell Res; 1993 Aug; 207(2):388-97. PubMed ID: 7688316
[TBL] [Abstract][Full Text] [Related]
18. Glucuronidation of SN-38 and NU/ICRF 505 in human colon cancer and adjacent normal colon.
Cummings J; Ethell BT; Jardine L; Burchell B
Anticancer Res; 2006; 26(3B):2189-96. PubMed ID: 16821585
[TBL] [Abstract][Full Text] [Related]
19. ICRF-193 modifies etoposide-induced apoptosis in thymocytes.
Tanimoto C; Hirakawa S; Kawasaki H; Hayakawa N; Ota Z
Acta Med Okayama; 1995 Dec; 49(6):281-6. PubMed ID: 8770236
[TBL] [Abstract][Full Text] [Related]
20. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
